Methods for the treatment of fatty liver disease

Abstract

This disclosure provides a method for treating fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / hepatic fibrosis improvement) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. This disclosure also provides a method for improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / enhancement of liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.